Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism

Transplantation

Volumn 99, Issue 2, 2015, Pages 351-359

  Pihlstrøm, Hege ^a   Dahle, Dag Olav ^a   Mjøen, Geir ^b   Pilz, Stefan ^c,d   März, Winfried ^c,e,f   Abedini, Sadollah ^g   Holme, Ingar ^b   Fellström, Bengt ^h   Jardine, Alan G ⁱ   Holdaas, Hallvard ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e SYNLAB ACADEMY   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g VESTFOLD HOSPITAL TRUST   (Norway)

^h UPPSALA UNIVERSITY HOSPITAL   (Sweden)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE; BIOLOGICAL MARKER; PTH PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COHORT ANALYSIS; CORRELATIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; HYPERPARATHYROIDISM; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME; ADVERSE EFFECTS; BLOOD; CARDIOVASCULAR DISEASES; CHI SQUARE DISTRIBUTION; COMPLICATION; GRAFT SURVIVAL; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TIME; UPREGULATION;

ADULT; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; FEMALE; GRAFT SURVIVAL; HUMANS; HYPERPARATHYROIDISM; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PARATHYROID HORMONE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84923015231     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000583     Document Type: Article

References (56)

1. Evenepoel P. Recovery versus persistence of disordered mineral metabolism in kidney transplant recipients. Semin Nephrol 2013; 33:191.
2. Bleskestad IH, Bergrem H, Leivestad T, Goransson LG. Intact parathyroid hormone levels in renal transplant patients with normal transplant function. Clin Transplant 2011;25:E566.
3. Nakamura M, Tanaka K, Marui Y, Tomikawa S. Clinicopathological analysis of persistent hypercalcemia and hyperparathyroidism after kidney transplantation in long-term dialysis patients. Ther Apher Dial 2013;17:551.
4. Koch Nogueira PC, David L, Cochat P. Evolution of secondary hyperparathyroidism after renal transplantation. Pediatr Nephrol 2000; 14:342.
5. Evenepoel P, Kuypers D, Maes B, Messiaen T, Vanrenterghem Y. Persistent hyperparathyroidism after kidney transplantation requiring parathyroidectomy. Acta Otorhinolaryngol Belg 2001;55:177.
6. Torres A, Rodriguez AP, Concepcion MT, et al. Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations. Nephrol Dial Transplant 1998;13(Suppl 3):94.
7. Lobo PI, Cortez MS, Stevenson W, Pruett TL. Normocalcemic hyperparathyroidism associated with relatively low 1:25 vitamin D levels postrenal transplant can be successfully treated with oral calcitriol. Clin Transplant 1995;9:277.
8. Giannini S, Sella S, Silva Netto F, et al. Persistent secondary hyperparathyroidism and vertebral fractures in kidney transplantation: role of calcium-sensing receptor polymorphisms and vitamin D deficiency. J Bone Miner Res 2010;25:841.
9. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006;82:603.
10. Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 2011; 378:1419.
11. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11:450.
12. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004;4:378.
13. Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011;378:1428.
14. Smogorzewski M, Zayed M, Zhang YB, Roe J, Massry SG. Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Am J Physiol 1993;264:H1998.
15. Schluter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 1998;37:34.
16. Yu N, Donnan PT, Flynn RW, et al. Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf) 2010;73:30.
17. Hagstrom E, Hellman P, Larsson TE, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009;119:2765.
18. Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone levels predict coronary heart disease: the Tromso Study. Eur J Cardiovasc Prev Rehabil 2004;11:69.
19. Pilz S, Tomaschitz A, Drechsler C, et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 2010;31:1591.
20. Rostand SG, Drueke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56:383.
21. Floege J, Kim J, Ireland E, et al. SerumiPTH, calciumand phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011;26:1948.
22. Natoli JL, Boer R, Nathanson BH, et al. Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis. BMC Nephrol 2013;14:88.
23. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024.
24. Holdaas H, Fellstrom B, Holme I, et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. J Cardiovasc Risk 2001;8:63.
25. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461.
26. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med 2010;29:1037.
27. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology. 1995;6:356-365.
28. Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N. Hyperparathyroidism and long-term bone loss after renal transplantation. Clin Transplant 2003;17:268.
29. Perrin P, Caillard S, Javier RM, et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant 2013;13:2653.
30. Roodnat JI, van Gurp EA,Mulder PG, et al. High pretransplant parathyroid hormone levels increase the risk for graft failure after renal transplantation. Transplantation 2006;82:362.
31. Molnar MZ, Kovesdy CP, Mucsi I, Salusky IB, Kalantar-Zadeh K. Association of pre-kidney transplant markers of mineral and bone disorder with post-transplant outcomes. Clin J Am Soc Nephrol 2012;7:1859.
32. Wolf M, Molnar MZ, Amaral AP, et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011;22:956.
33. Bleskestad I, Bergrem H, Leivestad T, Hartmann A, Gøransson L. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function. Clin Transplant 2014;28:479-486.
34. Fitzpatrick LA, Bilezikian JP, Silverberg SJ. Parathyroid hormone and the cardiovascular system. Curr Osteoporos Rep 2008;6:77.
35. Snijder MB, Lips P, Seidell JC, et al. Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. J Intern Med 2007;261:558.
36. Saleh FN, Schirmer H, Sundsfjord J, Jorde R. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 2003;24:2054.
37. Khouzam RN, Dishmon DA, Farah V, Flax SD, Carbone LD, Weber KT. Secondary hyperparathyroidism in patients with untreated and treated congestive heart failure. Am J Med Sci 2006;331:30.
38. Fritsch S, Lindner V, Welsch S, et al. Intravenous delivery of PTH/PTHrP type 1 receptor cDNA to rats decreases heart rate, blood pressure, renal tone, renin angiotensin system, and stress-induced cardiovascular responses. J Am Soc Nephrol 2004;15:2588.
39. Huang Z, Li J, Jiang Z, Qi Y, Tang C, Du J. Effects of adrenomedullin, C-type natriuretic peptide, and parathyroid hormone-related peptide on calcification in cultured rat vascular smooth muscle cells. J Cardiovasc Pharmacol 2003;42:89.
40. Torres PA, De Broe M. Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease. Kidney Int 2012;82:19.
41. Alam MU, Kirton JP, Wilkinson FL, et al. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res 2009;81:260.
42. Bjorkman MP, Sorva AJ, Tilvis RS. Elevated serum parathyroid hormone predicts impaired survival prognosis in a general aged population. Eur J Endocrinol 2008;158:749.
43. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208.
44. van Ballegooijen AJ, Reinders I, Visser M, et al. Serum parathyroid hormone in relation to all-cause and cardiovascular mortality: the Hoorn study. J Clin Endocrinol Metab 2013;98:E638.
45. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519.
46. Herzog CA, Mangrum JM, Passman R. Sudden cardiac death and dialysis patients. Semin Dial 2008;21:300.
47. Deo R, Katz R, Shlipak MG, et al. Vitamin D, parathyroid hormone, and sudden cardiac death: results from the Cardiovascular Health Study. Hypertension 2011;58:1021.
48. Custodio MR, Koike MK, Neves KR, et al. Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system. Nephrol Dial Transplant 2012;27:1437.
49. Bogin E, Massry SG, Harary I. Effect of parathyroid hormone on rat heart cells. J Clin Invest 1981;67:1215.
50. Egbuna OI, Taylor JG, Bushinsky DA, Zand MS. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant 2007;21:558.
51. Messa P, Cafforio C, Alfieri C. Clinical impact of hypercalcemia in kidney transplant. Int J Nephrol 2011;2011:906832.
52. Schwarz A, Mengel M, Gwinner W, et al. Risk factors for chronic allograft nephropathy after renal transplantation: a protocol biopsy study. Kidney Int 2005;67:341.
53. Gwinner W, Suppa S, Mengel M, et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005;5:1934.
54. Barenbrock M, Hausberg M, Kosch M, Kisters K, Hoeks AP, Rahn KH. Effect of hyperparathyroidism on arterial distensibility in renal transplant recipients. Kidney Int 1998;54:210.
55. Suwelack B, Gerhardt U, Witta J, Hillebrandt U, Hohage H. Effect of parathyroid hormone levels on carotid intima-media thickness after renal transplantation. Am J Hypertens 2001;14:1012.
56. Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 2004;19:1281.